Full-Time

Oncology Account Manager

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

501-1,000 employees

Develops cortisol modulators for medical conditions

Compensation Overview

$184k - $215k/yr

Senior, Expert

Union City, NJ, USA

Category
Strategic Account Management
Sales & Account Management
Required Skills
Data Analysis
Requirements
  • Proven track record of successful product launches and driving sales growth in a competitive oncology market
  • Established relationships with medical oncologists, gynecologic oncologists, and cancer centers within the assigned region
  • Possess deep knowledge of geography-specific drivers, including oncology treatment pathways, local market dynamics, and the reimbursement landscape
  • Strong business acumen with the ability to analyze data and develop strategic action plans
  • Ability to work independently and cross-functionally in a fast-paced, entrepreneurial launch environment
  • Willingness to travel 50-75% within the territory
Responsibilities
  • Primary responsibility is to achieve sales goals and ensure high quality interactions with each customer while navigating diverse account dynamics which influence patient access
  • Execute account-based plans that bring solutions to HCPs, care teams, and decision makers at cancer centers that enable productive education on the product’s clinical benefits, safety profile, and appropriate patient selection
  • Collaborate with cross-functional partners, including marketing, medical affairs, and market access, while consistently applying compliant communication to optimize product positioning and reimbursement strategies
  • Contribute to a positive, high-performing culture through continuous self-development, a willingness to challenge the status quo, and a strong sense of accountability, integrity, and grit
  • Conduct regular assessments of market dynamics, competitive landscape, and access barriers to identify opportunities and challenges
  • Ensure compliance with all laws, regulations and policies that govern the conduct of all activities
  • Be a valued member of the Oncology community by representing the company at national and regional oncology Congresses, and industry events
  • Ensure our actions align with Corcept ethics and patient-first principles through collaboration, embracing possibilities, following the data, and leading by doing
Desired Qualifications
  • Bachelor’s degree in a relevant field (Life Sciences, Business, or related discipline)
  • 10 years’ industry sales experience with a minimum of 5+ years focused on oncology sales with a strong preference for experience in gynecologic oncology and/or ovarian cancer, or related oncology subspecialties
  • Experience launching a new oncology product in a start-up or growth-stage pharmaceutical company

Corcept Therapeutics specializes in developing treatments that regulate cortisol, a hormone important for stress response, metabolism, and immune function. The company focuses on creating cortisol modulators to address serious medical conditions, particularly Cushing's syndrome, which is caused by excessive cortisol levels. Its main product, Korlym (mifepristone), is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome patients, launched in 2012. Corcept has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to healthcare professionals and patients to enhance understanding and care for cortisol-related disorders. The company's goal is to improve patient outcomes through effective treatments and education.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Corcept's stock is the best performing pharma stock in 2025.
  • The MOMENTUM trial could expand Corcept's market reach.
  • Corcept's NDA filing for a new drug shows active portfolio expansion.

What critics are saying

  • Securities fraud investigations could harm Corcept's reputation and finances.
  • Teva's antitrust lawsuit may lead to legal challenges for Corcept.
  • Potential market share loss due to legal issues with Korlym.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few competitors.
  • Korlym is the first FDA-approved treatment for Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

1%

2 year growth

-3%
Business Wire
Apr 23rd, 2025
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

CORCEPT to present late-breaking data from pivotal Phase 3 ROSELLA trial of Relacorilant in platinum-resistant Ovarian Cancer at ASCO 2025.

Access News Wire
Mar 18th, 2025
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud Investigation - CORT

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.

Stock Titan
Mar 10th, 2025
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.

PR Newswire
Mar 3rd, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Insider Monkey
Feb 23rd, 2025
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.